Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
President Trump on Tuesday announced a deal with Pfizer to sell its drugs directly to consumers at discounted prices. They'll be available through a website operated by the federal government.
-
The Trump administration sent letters this summer to 17 makers of name-brand drugs pushing them to lower prices to align them with what other countries pay. The companies had 60 days to "step up."
-
President Trump's announcement this week linking Tylenol with autism could play a role in ongoing legal cases against the company that makes it.
-
As coverage of this year's crop of COVID boosters hangs in the balance under Robert F. Kennedy Jr.'s leadership, what is the vaccine supply situation this year?
-
President Trump signed a memo on Tuesday directing the FDA to crack down on direct-to-consumer drug advertisements. But there are limits to what any administration can do.
-
For women with hair loss, there are more treatment options than ever before — and more ways to access them, as anyone scrolling social media has likely seen firsthand. But it can be confusing.
-
President Trump is pushing drugmakers to move production back to the United States. He's upping the ante with tariffs to encourage the shift. But would tariffs on imported drugs be enough?
-
President Trump is pushing drugmakers to move production back to the United States. He's upping the ante with tariffs to encourage the shift. But would tariffs on imported drugs be enough?
-
The first new non-opioid for severe acute pain has been on the market for a few months. But it's a lot more expensive than opioids, and many people can't get it because of spotty insurance coverage.
-
Thimerosal has been a target of groups that question vaccine safety. What vaccines still contain the mercury compound, and what would happen if the recommendations against its use become official?